Chugai Pharmaceutical and Araris Biotech have partnered in a research and licensing deal worth up to $780 million, using Araris’s AraLinQ platform to develop ADCs with Chugai’s antibodies against undisclosed targets. 

According to the RCO Agreement, Chugai will provide an upfront payment, cover all research costs, and handle development, manufacturing, and global commercialization once the option is exercised.  

Araris may receive up to $780 million in milestone payments, along with royalties on net sales, if Chugai meets certain development, regulatory, and commercial milestones.